Chinese Prescription Kangen-karyu against Metabolic Syndrome: Successful Treatment of Three Patients

Tsutomu Kitazawa (Shinseikai Toyama Hospital, Toyama, 939-0243, Japan)
Kazuyuki Hiratani (Shinseikai Toyama Hospital, Toyama, 939-0243, Japan)
Chan Hum Park (Institute of New Frontier Research Team, Hallym Clinical and Translational Science Institute, Hallym University,Chuncheon, 24252, Republic of Korea)
Takako Yokozawa (Graduate School of Science and Engineering for Research, University of Toyama, Toyama, 930-8555, Japan)

Article ID: 3230

DOI: https://doi.org/10.30564/jim.v10i1.3230

Abstract


Metabolic syndrome is the cluster of diseases, which is manifested by central obesity, impaired glucose tolerance, lipodystrophy, and high blood pressure. These metabolic syndrome-related traits significantly increase the risk of type 2 diabetes, adverse cardiac events, stroke, and hepatic steatosis. In the past decade, several organizations have proposed different diagnostic criteria. The use of traditional Chinese medicine to treat metabolic syndrome has received increasing attention due to its wide availability. In this paper, we report a case of three patients with metabolic syndrome with improved administration of 7.5 g of Kangen-karyu extract per day for 6 months. We present and discuss evidence supporting the possibility of using Kangenkaryu for metabolic syndrome.


Keywords


Metabolic syndrome;Traditional Chinese medicine;Kangen-karyu;Case report

Full Text:

PDF

References


[1] Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, Conference Participants. Clinical management of metabolic syndrome. Report of the Americal Heart Association/National Heart, Lung,and Blood Institute/Americal Diabetes Association Conference on scientific issues related to management. Circulation 2004;109(4):551-6.

[2] Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL.Metabolic syndrome: pathophysiology,management,and modulation by natural compounds. Ther Adv Cardiovasc Dis 2017;11(8):215-25.

[3] Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20(2):12.

[4] Kylin E. Studien ueber das hypertonie-hyperglyka “mie-hyperurika” miesyndrom. Zentralblatt fuer Innere Medizin 1923;44:105-27.

[5] Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607.

[6] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med 1998;15(7):539-53.

[7] Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med 1999;16(5):442-3.

[8] Evaluation Committee on Diagnostic Criteria for Metabolic Syndrome. Metabolic syndrome: defi nitions and diagnostic criteria. J Jpn Soc Int Med 2005;94(4):794-809.

[9] Hunt KJ, Resendez RG, Williams K, Haffner SM,Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110(10):1251-7.

[10] Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110(10):1245-50.

[11] Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, Shimamoto K. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Eduction Program-Adult Treatment Panel III to Japanese men- -the Tanno and Sobetsu Study. Hypertens Res 2005;28(3):203-8.

[12] Makino T, Wakushima H, Okamoto T, Okukubo Y,Deguchi Y, Kano Y. Pharmacokinetic and pharmacological interactions between ticlopidine hydrochloride and Kangen-karyu – Chinese traditional herbal medicine. Phytother Res 2003;17(9):1021-4.

[13] Yokozawa T, Cho EJ, Sasaki S, Satoh A, Okamoto T, Sei Y. The protective role of Chinese prescription Kangen-karyu extract on diet-induced hypercholesterolemia in rats. Biol Pharm Bull 2006;29(4):760-5.

[14] Yokozawa T, Kim HJ, Yamabe N, Okamoto T, Cho EJ. The protective role of Kangen-karyu against fructose-induced metabolic syndrome in a rat model. J Pharm Pharmacol 2007;59(9):1271-8.

[15] Noh JS, Park CH, Kim HY, Zhao Q, Yamabe N,Matsumoto K, Yokozawa T. Chinese prescription Kangen-karyu prevents dyslipidaemia and oxidative stress in mouse model of type 2 diabetes. J Pharm Pharmacol 2011;63(1):111-9.

[16] Xu LN, Yin ZZ, Ou YR. The effect of compositus Guan-Xin NO 2 on myocardial ischaemia and hypoxia in experimental animals. Yao Xue Xue Bao 1979;14(8):461-6.

[17] Qin F, Huang X. Guanxin II (II) for the management of coronary heart disease. Chin J Integr Med 2009;15(6):472-6.

[18] Botev R, Mallié JP, Couchoud C, Schück O, Fauvel JP, Wetzels JFM, Lee N, De Santo NG, Cirillo M.Estimating glomerular filtration rate: Cockcroft-Gault and modification of diet in renal disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol 2009;4(5):899-906.

[19] Agarwal DP. Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol 2002;37(5):409-15.

[20] Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, Bouret S, Varma V,Hastings KL,Schug TT, Hart SGE, Burleson FG. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci 2018;162(1):36-42.

[21] Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med 1998;158(20):2192-9.

[22] Takahashi M, Sugaya K, Kubota K. Kangenkaryu prevents the decrease of cholinergic markers following the nucleus basalis magnocellularis lesion. Jpn J Pharmacol 1992;60(3):307-10.

[23] Gao M, Ikeda K, Noguchi T, Mori K, Yamori Y.Studies on preventive effect of ‘Kangenkaryu’,Chinese herbal medicine, on stroke in SHR-SP. J Trad Med 2001;18(6):245-50.

[24] Makino T, Wakushima H, Okamoto T, Okukubo Y,Saito K, Kano Y. Effects of Kangen-karyu on coagulation system and platelet aggregation in mice. Biol Pharm Bull 2002;25(4):523-5.

[25] Pu F, Kaneko T, Enoki M, Irie K, Okamoto T, Sei Y, Egashira N, Oishi R, Mishima K, Kamimura H,Iwasaki K, Fujiwara M. Ameliorating effects of Kangen-karyu on neuronal damage in rats subjected to repeated cerebral ischemia. J Nat Med 2010;64(2):167-74.

[26] Yamabe N, Kim HY, Kang KS, Zhao Q, Matsumoto K, Yokozawa T. Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice. J Ethnopharmacol 2010;129(3):299-305.

[27] Zhao Q, Yokozawa T, Yamabe N, Tsuneyama K, Li X, Matsumoto K. Kangen-karyu improves memory deficit caused by aging through normalization of neuro-plasticity-related signaling system and VEGF system in the brain. J Ethnopharmacol 2010;131(2):377-85.

[28] Anastasi JK, Currie LM, Kim GH. Understanding diagnostic reasoning in TCM practice: tongue diagnosis. Altern Ther Health Med 2009;15(3):18-28.

[29] Lee TC, Lo LC, Wu FC. Traditional Chinese medicine for metabolic syndrome via TCM pattern differentiation: tongue diagnosis for predictor. Evid Based Complementary Altern Med 2016;2016:Article ID 1971295, 8 pages.

[30] Yoon YS, Oh SW, Baik HW, Park HS, Kim WY.Alcohol consumption and the metabolic syndrome in Korean adults: the 1998 Korean National Health and Nutrition Examination Survey. Am J Clin Nutr 2004;80(1):217-24.

[31] Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ.Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet 1977;2(8030):153-5.

[32] Marmot MG, Elliott P, Shipley MJ, Dyer AR, Ueshima H, Beevers DG, Stamler R, Kesteloot H,Rose G,Stamler J. Alcohol and blood pressure: the INTERSALT study. BMJ 1994;308(6939):1263-7.

[33] Freiberg MS, Cabral HJ, Heeren TC, Vasan RS,Ellison RC, Third National Health and Nutrition Examination Survey. Alcohol consumption and the prevalence of the metabolic syndrome in the US.:a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey.Diabetes Care 2004;27(12):2954-9.


Refbacks

  • There are currently no refbacks.
Copyright © 2021 Tsutomu Kitazawa, Kazuyuki Hiratani, Chan Hum Park, Takako Yokozawa


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.